Libra Infusions disclosing pending financial results | The Business Standard
Skip to main content
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Thursday
July 03, 2025

Sign In
Subscribe
  • Latest
  • Economy
    • Banking
    • Stocks
    • Industry
    • Analysis
    • Bazaar
    • RMG
    • Corporates
    • Aviation
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
THURSDAY, JULY 03, 2025
Libra Infusions disclosing pending financial results

Stocks

TBS Report
12 July, 2022, 09:30 pm
Last modified: 12 July, 2022, 11:12 pm

Related News

  • HC directs Al-Arafah Bank to provide financial assistance, claims Libra Infusions
  • Khan Brothers, Libra Infusions clarify operational status
  • Libra Infusions made a profit in three-quarters of FY22
  • Why Libra Infusion shares climb to nine-month high 
  • Libra Infusions allowed to pay 50% stock dividend

Libra Infusions disclosing pending financial results

TBS Report
12 July, 2022, 09:30 pm
Last modified: 12 July, 2022, 11:12 pm

Libra Infusions Ltd has finally begun to disclose its financial results that have been pending since mid-2019.

Predictably, it has had losses for the first nine months of fiscal year 2019-20.

With a mixture of small profits in the first three months and much bigger losses in the next six months, the intravenous fluids producer posted Tk5.24 in losses per share (negative earnings per share or negative EPS) for the July 2019 to March 2020 period.

The unaudited losses appeared to have been much smaller than the negative EPS of Tk18.07 for the same nine months of the previous 2018-19 fiscal year, when an extraordinary fourth quarter helped the firm save its annual bottom line, posting Tk1.05 in annual EPS.

The Business Standard Google News Keep updated, follow The Business Standard's Google news channel

However, since the decline in earnings, the company stopped disclosing financials though it continued operating. 

In 2018, its business declined owing to disputes with its financier Al-Arafah Islami Bank Ltd, said Libra Infusions Company Secretary Md Shafiqul Islam Bhuyan.

The company built a second unit at its factory complex in the capital's Mirpur area, but due to the dispute with and no cooperation from the bank, its business was hurt back then, he said.

However, the dispute of Tk157.2 crore with the bank was settled by a Solenama made with the bank, before the High Court, he said.

The business is running and the company will publish its annual financial results for 2019-20 fiscal year on Thursday, he added.

Investors will still be in the dark about the 2020-21 and 2021-22 fiscal year  financial updates.

The fall of Libra Infusions

The producer of intravenous fluids, commonly known as injectable saline, started business in 1985 with a factory built with the technical assistance of a Swiss company.

In 2009, the company undertook a project to build a second unit at its Mirpur factory. For this, it took a loan of Tk84 crore from Al-Arafah Islami Bank, but the company began to collapse following a standoff over loan repayment.

A former Libra Infusions official, earlier this year claimed while talking to The Business Standard, that the Shariah-based bank had invested in Libra's Unit 2 at the time, but the project could not take off on time as the lender did not release funds in a timely manner. The company had to count losses.

And since the bank had invested here and the losses had been due to the lender, Libra did not repay the loan installments, and instead filed a case against the bank seeking compensation, he added.

Later in 2015, Al-Arafah Islami Bank filed a lawsuit against Dr Roushon Alam, managing director of Libra Infusions, on charges of threatening bank officials. The lender also filed 13 cases for bounced cheques and another one for the recovery of loans in default.

Dr Roushon Alam was arrested in connection with the cases and was later released on bail.

Also, in 2019, the bank issued a notice to sell Libra Infusions' assets at auction to recover loans in default, but as per a decision of the High Court, that did not see the light of day.

In such a tug-of-war between the two sides, Libra Infusions suffered a working capital shortfall affecting production, said the former official of the company.

He also said that despite being among the first companies in the country, at present, its business is lagging far behind others. Moreover, there is a lack of good governance in the company generating such tensions with the bank.

Earlier in 2017, the Bangladesh Securities and Exchange Commission (BSEC) fined Libra directors a total of Tk12 lakh for non-compliance in financial statements.

This time, the BSEC is yet to punish the company or its directors for the delays in publishing financial statements.

Libra Infusions shares having a face value of Tk10 each, closed 1.7% lower at Tk857.7 on the Dhaka Stock Exchange on Tuesday, while the company disclosed a net asset value of Tk1,264 per share as of 31 March, 2020. 

Top News / Corporates

Libra Infusions / Financial Reports

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Govt to pay 3-year high ACU bill of $2b next week
    Govt to pay 3-year high ACU bill of $2b next week
  • A file photo of the NBR Bhaban in Agargaon, Dhaka
    NBR officers gripped by fear as govt gets tough  
  • History in women's football: Bangladesh qualify for Asian Cup for the first time
    History in women's football: Bangladesh qualify for Asian Cup for the first time

MOST VIEWED

  • Govt lowers interest rates on savings instruments
    Govt lowers interest rates on savings instruments
  • File photo of Bangladesh Public Service Commission logo. Photo: Collected
    Repeat recommendations in 44th BCS spark vacancy fears
  • File photo of Chattogram Port/TBS
    Ctg port handles record 32.96 lakh containers in FY25, revenue hits Tk75,432 crore
  • Chief adviser’s Special Envoy for International Affairs and Adviser Lutfey Siddiqi
    Fake documents submission behind visa complications for Bangladeshis: Lutfey Siddiqi
  • Zakir Hossain. Photo: Collected
    Ctg customs commissioner suspended for joining NBR officials' 'complete shutdown'
  • Controversial taxman Matiur’s rulings cost govt Tk1000cr in lost revenue
    Controversial taxman Matiur’s rulings cost govt Tk1000cr in lost revenue

Related News

  • HC directs Al-Arafah Bank to provide financial assistance, claims Libra Infusions
  • Khan Brothers, Libra Infusions clarify operational status
  • Libra Infusions made a profit in three-quarters of FY22
  • Why Libra Infusion shares climb to nine-month high 
  • Libra Infusions allowed to pay 50% stock dividend

Features

Illustration: TBS

The buildup to July Uprising: From a simple anti-quota movement to a wildfire against autocracy

2h | Panorama
Illustration: TBS

Ulan Daspara: Remnants of a fishing village in Dhaka

2d | Panorama
Photo: Collected

Innovative storage accessories you’ll love

3d | Brands
Two competitors in this segment — one a flashy newcomer, the other a hybrid veteran — are going head-to-head: the GAC GS3 Emzoom and the Toyota CH-R. PHOTOS: Nafirul Haq (GAC Emzoom) and Akif Hamid (Toyota CH-R)

GAC Emzoom vs Toyota CH-R: The battle of tech vs trust

3d | Wheels

More Videos from TBS

Will Syria normalise relations with Israel?

Will Syria normalise relations with Israel?

1h | Others
Multinational companies' participation in the Israeli massacre in Gaza

Multinational companies' participation in the Israeli massacre in Gaza

2h | Others
July fighter Fahim doesn't want to be a burden.

July fighter Fahim doesn't want to be a burden.

2h | TBS Stories
The government has reduced the profit on savings certificates; what is its impact on the common man?

The government has reduced the profit on savings certificates; what is its impact on the common man?

4h | Podcast
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net